Antiepileptic drugs 2012: Recent advances and trends

Mayo Clinic Proceedings

Volumn 87, Issue 9, 2012, Pages 879-889

  Sirven, Joseph I ^a   Noe, Katherine ^a   Hoerth, Matthew ^a   Drazkowski, Joseph ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CORTICOTROPIN; DIAZEPAM; DIGOXIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FLUCONAZOLE; FLUVOXAMINE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LORAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; PRIMIDONE; RETIGABINE; RUFINAMIDE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; AGGRESSION; ARTICLE; ATAXIA; ATONIC SEIZURE; CONFUSION; DIABETIC NEUROPATHY; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EPILEPSY; FATIGUE; FOCAL EPILEPSY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; INFANTILE SPASM; INSOMNIA; LENNOX GASTAUT SYNDROME; LETHARGY; LOW DRUG DOSE; MENTAL DISEASE; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PREDICTION; QT PROLONGATION; RECOMMENDED DRUG DOSE; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT RESPONSE; TREND STUDY; UNITED STATES; URINE RETENTION; VAGUS NERVE STIMULATION; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; WEIGHT GAIN;

EID: 84866368274     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.05.019     Document Type: Review

References (37)

1. Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010; 9(1):68-82.
2. Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia. 1999;40(11):1471-1483. (Pubitemid 29518074)
3. Webanatomy. Excitability and Membrane Electropotential. http://webanatomy.net/237/channels/channels.htm. Accessed July 27, 2012.
4. Brickel N, HJ, DeRossett S. Pharmacological effects of retigabine on bladder function: results from phase 2/3 studies. In: Proceedings from the American Epilepsy Society; December 2010; San Antonio, TX. Abstract 1.272.
5. Brandt C, Heile A, Potschka H, Stoehr T, Löscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia. 2006;47(11):1803-1809. (Pubitemid 44730049)
6. Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K(-) channel opener for the treatment of epilepsy. Epilepsia. 2012;53(3):412-424.
7. Large CH, Sokal DM, Nehlig A, et al. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia. 2012;53(3):425-436.
8. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the K 7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol. 2005;67(4):1009-1017. (Pubitemid 40410403)
9. Food and Drug Administration. Sabril [product label]. Deer-field, IL: Lundbeck; 2009.
10. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia. 2009;50(2): 163-173.
11. Wohlrab G, Leiba H, Kastle R, et al. Vigabatrin therapy in infantile spasms: solving one problem and inducing another? Epilepsia. 2009;50(8):2006-2008.
12. Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia. 2008;49(1):108-116.
13. Maguire MJ, Hemming K, Wild JM, Hutton JL, Marson AG. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia. 2010;51(12):2423-2431.
14. Food and Drug Administration. Banzel [product label]. Baltimore, MD: Eisai Inc; 2011.
15. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950-1958.
16. Food and Drug Administration. Vimpat [product label]. Brussels, Belgium: UCB Inc; 2009.
17. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007; 48(7):1308-1317. (Pubitemid 47063096)
18. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51(6):958-967.
19. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50(3):443-453.
20. Food and Drug Administration. Onfi [product label]. Deer-field, IL: Lundbeck; 2011.
21. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA; OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77(15):1473-1481.
22. Food and Drug Administration. Potiga [product label]. Columbia, MD: GlaxoSmithKline; 2011.
23. French JA, Abou-Khalil B, Leroy RF. Randomized placebocontrolled trial ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76(18):1555-1563.
24. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM; 205 Study Group. Randomized, multicentre dose ranging trial of retigabine for partial onset seizures. Neurology. 2007;68(15): 1197-2004.
25. Chen P, Lin JJ, Lu CS. Carbamazepine-induced toxic effects and HLA B*1502 screening in Taiwan. N Engl J Med. 2011; 364(12):1126-1133.
26. Chung WH, Hung SI, Hong HS. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.
27. McCormack M, Alfirevic A, Bourgeois S. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134-1143.
28. Research CfDEa. Antiepileptic Drugs and Suicidality. 2008. www.fda.gov/ohrms/dockets/ac/08/slides/2008-4372s1-03-FDA.ppt. Accessed August 9, 2012.
29. Treatment CfDEa. Antiepileptic Drugs and Suicidality. 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf. Accessed August 9, 2012.
30. Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med. 2010;363(6):542-551.
31. Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology. 2010;75(4):335-340.
32. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48(3):464-469. (Pubitemid 46365174)
33. Liow K, Barkley GL, Pollard Jr. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology. 2007;68(16):1249-1250. (Pubitemid 46625968)
34. Berg MJ, Gross RA, Haskins LS. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav. 2008;13(4):693-699.
35. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. 2008;71(7):525-530.
36. Committee PSaCPA. Meeting Materials for Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. Washington, DC: Food and Drug Administration; 2010.
37. Krauss GL, Caffo B, Chang YT, Hendrix CW, Chuang K. Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol. 2011;70(2):221-228.